344897-95-6
中文名稱
4-(5-((3-芐基-4-氧代-2-硫代噻唑烷-5-亞基)甲基)呋喃-2-基)苯甲酸
英文名稱
Leukadherin 1
CAS
344897-95-6
分子式
C22H15NO4S2
分子量
421.49
MOL 文件
344897-95-6.mol
更新日期
2025/01/07 00:58:22
344897-95-6 結(jié)構(gòu)式
基本信息
中文別名
4-(5-((3-芐基-4-氧代-2-硫代噻唑烷-5-亞基)甲基)呋喃-2-基)苯甲酸 英文別名
CS-2237eukadherin-1
Leukadherin-1
Leukadherin 1
Leukadhedrin 1
LA1(Leukadherin-1)
LEUKADHERIN 1
LEUKADHERIN1
4-(5-((3-Benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid
4-[5-[[4-Oxo-3-(phenylmethyl)-2-thioxo-5-thiazolidinylidene]methyl]-2-furanyl]-benzoic acid
Benzoic acid, 4-[5-[[4-oxo-3-(phenylmethyl)-2-thioxo-5-thiazolidinylidene]methyl]-2-furanyl]-
物理化學(xué)性質(zhì)
沸點(diǎn)634.7±65.0 °C(Predicted)
密度1.50±0.1 g/cm3(Predicted)
儲(chǔ)存條件Sealed in dry,2-8°C
溶解度DMSO：可溶，3mg/mL，澄清（加熱）
酸度系數(shù)(pKa)4.11±0.10(Predicted)
形態(tài)粉末
顏色黃色到橙色到棕色
4-(5-((3-芐基-4-氧代-2-硫代噻唑烷-5-亞基)甲基)呋喃-2-基)苯甲酸價(jià)格(試劑級(jí))
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2024/11/08 | HY-15701 | 4-(5-((3-芐基-4-氧代-2-硫代噻唑烷-5-亞基)甲基)呋喃-2-基)苯甲酸 Leukadherin-1 | 344897-95-6 | 5 mg | 450元 |
| 2024/11/08 | HY-15701 | 4-(5-((3-芐基-4-氧代-2-硫代噻唑烷-5-亞基)甲基)呋喃-2-基)苯甲酸 Leukadherin-1 | 344897-95-6 | 10mM * 1mLin DMSO | 495元 |
| 2024/11/08 | HY-15701 | 4-(5-((3-芐基-4-氧代-2-硫代噻唑烷-5-亞基)甲基)呋喃-2-基)苯甲酸 Leukadherin-1 | 344897-95-6 | 10mg | 720元 |
常見問題列表
生物活性
Leukadherin-1 是特異性的白細(xì)胞表面整合素 CD11b/CD18 的激動(dòng)劑。Leukadherin-1 可增加 CD11b/CD18 依賴性細(xì)胞對(duì)血纖蛋白原的粘附，EC50為 4 μM。Leukadherin-1 增強(qiáng)白細(xì)胞對(duì)配體 (如 ICAM-1) 和血管內(nèi)皮的粘附，從而減少白細(xì)胞跨內(nèi)皮遷移和流入損傷部位。Leukadherin-1 抑制先天性炎癥信號(hào)轉(zhuǎn)導(dǎo)。體外研究
Leukadherin-1 is a specific agonist of the leukocyte surface integrin CD11b/CD18 (αMβ2; CR3; Mac-1). Leukadherin‐1 pretreatment reduces secretion of interferon (IFN)‐γ, tumour necrosis factor (TNF) and macrophage inflammatory protein (MIP)‐1β by monokine‐stimulated NK cells. Leukadherin‐1 pretreatment also reduces secretion of IL‐1β, IL‐6 and TNF by Toll‐like receptor (TLR)‐2 and TLR‐7/8‐stimulated monocytes.
體內(nèi)研究
Leukadherin-1 (1 mg/kg; i.p.; twice daily for 14 days) is beneficial in preventing hyperoxia-induced neonatal lung injury, an experimental model of bronchopulmonary dysplasia (BPD).
| Animal Model: | Newborn Sprague Dawley rat pups |
| Dosage: | 1 mg/kg |
| Administration: | I.p.; twice daily for 14 days |
| Result: | Beneficial on preventing the lung inflammatory response, improved alveolarization and vascular development, and reduced pulmonary vascular remodeling and PH in a hyperoxia-induced experimental model of BPD. |